Pooya Mobadersany
Pooya Mobadersany has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Lee Alex Donald Cooper
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
11 shared publications - David A. Gutman
Emory University, Department of Pathology, GA, USA
10 shared publications Hagar Hussein
10 shared publications- Mohamed Amgad
Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA
10 shared publications Brian P. Pollack
9 shared publicationsHabiba Elfandy
9 shared publications
Latest Publications
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400653
Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer
PURPOSE: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histopathology–based multimodal artificial intelligence (MMAI) algorithm to estimate clinical outcomes in SPARTAN. METHODS: Patients with available hematoxylin and eosin-stained slides from the primary tumor were included. Histopathology slides were digitized. MMAI scores ranging from 0 to 1 were generated from digital histopathology and baseline clinical parameters. Patients were categorized into MMAI non–high-risk and high-risk groups using previously validated cutoffs. Kaplan-Meier estimates were calculated for metastasis-free survival (MFS), second progression-free survival (PFS2), and overall survival (OS); comparisons were performed using Cox proportional hazards regression for treatment arms and MMAI risk. The interaction between treatment arm and risk group was evaluated using a Cox proportional hazards model. RESULTS: The study included 420 evaluable patients after excluding those with missing clinical data or inadequate histopathology images. Of these, 63% (n = 266) were MMAI high risk and 37% (n = 154) were non–high risk. MMAI risk score was associated with shorter MFS (hazard ratio [HR], 1.72; P < .005), PFS2 (HR, 1.57; P < .005), and OS (HR, 1.41; P = .02). MMAI high-risk patients receiving apalutamide demonstrated significant improvement in MFS (HR, 0.19; P < .005), PFS2 (HR, 0.47; P < .005), and OS (HR, 0.6; P = .01). The interaction between MMAI risk score and treatment for MFS ( P = .01) and PFS2 ( P = .03) was significant, indicating greater benefit from apalutamide treatment in MMAI high-risk patients. CONCLUSION: MMAI is a prognostic marker in nmCRPC and may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide. These results represent the first extension of an MMAI classifier to patients with castration-resistant prostate cancer, warranting additional validation.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2400653
Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer
PURPOSE: The SPARTAN trial demonstrated that the addition of apalutamide to androgen deprivation therapy improves outcomes among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). We applied a previously reported digital histopathology–based multimodal artificial intelligence (MMAI) algorithm to estimate clinical outcomes in SPARTAN. METHODS: Patients with available hematoxylin and eosin-stained slides from the primary tumor were included. Histopathology slides were digitized. MMAI scores ranging from 0 to 1 were generated from digital histopathology and baseline clinical parameters. Patients were categorized into MMAI non–high-risk and high-risk groups using previously validated cutoffs. Kaplan-Meier estimates were calculated for metastasis-free survival (MFS), second progression-free survival (PFS2), and overall survival (OS); comparisons were performed using Cox proportional hazards regression for treatment arms and MMAI risk. The interaction between treatment arm and risk group was evaluated using a Cox proportional hazards model. RESULTS: The study included 420 evaluable patients after excluding those with missing clinical data or inadequate histopathology images. Of these, 63% (n = 266) were MMAI high risk and 37% (n = 154) were non–high risk. MMAI risk score was associated with shorter MFS (hazard ratio [HR], 1.72; P < .005), PFS2 (HR, 1.57; P < .005), and OS (HR, 1.41; P = .02). MMAI high-risk patients receiving apalutamide demonstrated significant improvement in MFS (HR, 0.19; P < .005), PFS2 (HR, 0.47; P < .005), and OS (HR, 0.6; P = .01). The interaction between MMAI risk score and treatment for MFS ( P = .01) and PFS2 ( P = .03) was significant, indicating greater benefit from apalutamide treatment in MMAI high-risk patients. CONCLUSION: MMAI is a prognostic marker in nmCRPC and may serve as a predictive biomarker with high-risk patients deriving the greatest benefit from treatment with apalutamide. These results represent the first extension of an MMAI classifier to patients with castration-resistant prostate cancer, warranting additional validation.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Whole-slide histology images contain information that is valuable for clinical and basic science investigations of cancer but extracting quantitative measurements from these images is challenging for researchers who are not image analysis specialists. In this article, we describe HistomicsML2, a software tool for learn-by-example training of machine learning classifiers for histologic patterns in whole-slide images. This tool improves training efficiency and classifier performance by guiding users to the most informative training examples for labeling and can be used to develop classifiers for prospective application or as a rapid annotation tool that is adaptable to different cancer types. HistomicsML2 runs as a containerized server application that provides web-based user interfaces for classifier training, validation, exporting inference results, and collaborative review, and that can be deployed on GPU servers or cloud platforms. We demonstrate the utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and cutaneous melanoma.Significance:An interactive machine learning tool for analyzing digital pathology images enables cancer researchers to apply this tool to measure histologic patterns for clinical and basic science studies.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Whole-slide histology images contain information that is valuable for clinical and basic science investigations of cancer but extracting quantitative measurements from these images is challenging for researchers who are not image analysis specialists. In this article, we describe HistomicsML2, a software tool for learn-by-example training of machine learning classifiers for histologic patterns in whole-slide images. This tool improves training efficiency and classifier performance by guiding users to the most informative training examples for labeling and can be used to develop classifiers for prospective application or as a rapid annotation tool that is adaptable to different cancer types. HistomicsML2 runs as a containerized server application that provides web-based user interfaces for classifier training, validation, exporting inference results, and collaborative review, and that can be deployed on GPU servers or cloud platforms. We demonstrate the utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and cutaneous melanoma.Significance:An interactive machine learning tool for analyzing digital pathology images enables cancer researchers to apply this tool to measure histologic patterns for clinical and basic science studies.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Supplementary figures and table legends.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Video 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessVideo 1 from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Whole-slide histology images contain information that is valuable for clinical and basic science investigations of cancer but extracting quantitative measurements from these images is challenging for researchers who are not image analysis specialists. In this article, we describe HistomicsML2, a software tool for learn-by-example training of machine learning classifiers for histologic patterns in whole-slide images. This tool improves training efficiency and classifier performance by guiding users to the most informative training examples for labeling and can be used to develop classifiers for prospective application or as a rapid annotation tool that is adaptable to different cancer types. HistomicsML2 runs as a containerized server application that provides web-based user interfaces for classifier training, validation, exporting inference results, and collaborative review, and that can be deployed on GPU servers or cloud platforms. We demonstrate the utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and cutaneous melanoma.Significance:An interactive machine learning tool for analyzing digital pathology images enables cancer researchers to apply this tool to measure histologic patterns for clinical and basic science studies.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Interactive Classification of Whole-Slide Imaging Data for Cancer Researchers
Whole-slide histology images contain information that is valuable for clinical and basic science investigations of cancer but extracting quantitative measurements from these images is challenging for researchers who are not image analysis specialists. In this article, we describe HistomicsML2, a software tool for learn-by-example training of machine learning classifiers for histologic patterns in whole-slide images. This tool improves training efficiency and classifier performance by guiding users to the most informative training examples for labeling and can be used to develop classifiers for prospective application or as a rapid annotation tool that is adaptable to different cancer types. HistomicsML2 runs as a containerized server application that provides web-based user interfaces for classifier training, validation, exporting inference results, and collaborative review, and that can be deployed on GPU servers or cloud platforms. We demonstrate the utility of this tool by using it to classify tumor-infiltrating lymphocytes in breast carcinoma and cutaneous melanoma.Significance:An interactive machine learning tool for analyzing digital pathology images enables cancer researchers to apply this tool to measure histologic patterns for clinical and basic science studies.
- Open Access
- 17 May 2022
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 11
NuCLS: A scalable crowdsourcing approach and dataset for nucleus classification and segmentation in breast cancer
Background: Deep learning enables accurate high-resolution mapping of cells and tissue structures that can serve as the foundation of interpretable machine-learning models for computational pathology. However, generating adequate labels for these structures is a critical barrier, given the time and effort required from pathologists. Results: This article describes a novel collaborative framework for engaging crowds of medical students and pathologists to produce quality labels for cell nuclei. We used this approach to produce the NuCLS dataset, containing >220,000 annotations of cell nuclei in breast cancers. This builds on prior work labeling tissue regions to produce an integrated tissue region- and cell-level annotation dataset for training that is the largest such resource for multi-scale analysis of breast cancer histology. This article presents data and analysis results for single and multi-rater annotations from both non-experts and pathologists. We present a novel workflow that uses algorithmic suggestions to collect accurate segmentation data without the need for laborious manual tracing of nuclei. Our results indicate that even noisy algorithmic suggestions do not adversely affect pathologist accuracy and can help non-experts improve annotation quality. We also present a new approach for inferring truth from multiple raters and show that non-experts can produce accurate annotations for visually distinctive classes. Conclusions: This study is the most extensive systematic exploration of the large-scale use of wisdom-of-the-crowd approaches to generate data for computational pathology applications.
- 17 May 2022
- Published by Oxford University Press (OUP) in GigaScience
- Vol. 11
Open AccessNuCLS: A scalable crowdsourcing approach and dataset for nucleus classification and segmentation in breast cancer
Background: Deep learning enables accurate high-resolution mapping of cells and tissue structures that can serve as the foundation of interpretable machine-learning models for computational pathology. However, generating adequate labels for these structures is a critical barrier, given the time and effort required from pathologists. Results: This article describes a novel collaborative framework for engaging crowds of medical students and pathologists to produce quality labels for cell nuclei. We used this approach to produce the NuCLS dataset, containing >220,000 annotations of cell nuclei in breast cancers. This builds on prior work labeling tissue regions to produce an integrated tissue region- and cell-level annotation dataset for training that is the largest such resource for multi-scale analysis of breast cancer histology. This article presents data and analysis results for single and multi-rater annotations from both non-experts and pathologists. We present a novel workflow that uses algorithmic suggestions to collect accurate segmentation data without the need for laborious manual tracing of nuclei. Our results indicate that even noisy algorithmic suggestions do not adversely affect pathologist accuracy and can help non-experts improve annotation quality. We also present a new approach for inferring truth from multiple raters and show that non-experts can produce accurate annotations for visually distinctive classes. Conclusions: This study is the most extensive systematic exploration of the large-scale use of wisdom-of-the-crowd approaches to generate data for computational pathology applications.